#nopatientleftbehind
knowing hidden and rare genomic drivers behind lung cancer unlocks new therapeutic possibilities. key biomarkers, like RET fusions, are being used in precision medicine – redefining cancer treatment.
the goals
/ grow awareness of the RET biomarker to accelerate interest and demand for RET alteration testing and targeted therapies.
/ create a compelling case for labs to adopt RET alteration testing, even though RET alteration exists in only 2% of newly diagnosed NSCLC patients. however, the new drug therapy is incredibly effective.
/ create a compelling case for labs to run CGP. most of the tissue will be exhausted if labs run each test separately. CGP can test for all recommended biomarkers in a single test with limited tissue biopsy, so patients with rare alterations will get the testing they need (#nopatientleftbehind).
